Parkinson’s UK is pleased to announce the release of the next tranche of funding to continue our collaboration with Selcia (part of Eurofins) and Cresset Discovery Services to create novel gene transcription modulators following excellent progress in the first 6 months of the project.
In March 2018, Parkinson’s UK announced funding of £1.2million to create molecules that increase the activity of a selection of genes which have the potential to both increase dopamine synthesis to ease symptoms, and boost the production of proteins which have neuroprotective effects.
Dr Richard Morphy, Drug Discovery Manager and leader of the programme at Parkinson’s UK, comments:
“We’re very pleased with the progress that is being made in this project which has successfully generated novel molecules that have exciting potential. We will now continue into the next stage of the work plan to develop and test these molecules further which we hope to complete by the end of 2018.”
Dr Vicky Steadman, Director of Discovery at Selcia, added:
“Selcia, now part of the Eurofins group, has a strong track record in Integrated Drug Discovery. Our predominantly ex-Big Pharma team are experienced in the design of molecules that enter the brain. We are pleased to continue this promising collaboration with Parkinson’s UK and Cresset.”
Dr Martin Slater, Director of Consulting at Cresset Discovery Services, says:
“I am delighted that our unique software, virtual screening capabilities and highly experienced team have contributed to Parkinson’s UK extending this three-way collaboration. We look forward to continuing to deliver molecular modelling support for the next phase of this important project.”